The soaring cost of prescription drugs in the United States is a persistent and deeply frustrating issue for millions of Americans. This complexity is not accidental; it’s a result of intricate legal and economic mechanisms, particularly the pharmaceutical patent system. A new series, "An Arm and a Leg 101," delves into the "why" behind these high costs and explores potential solutions. This installment focuses on a key driver of pharmaceutical expense: the strategic use of patents, often referred to as "patent thickets," to extend market exclusivity and delay the introduction of more affordable generic alternatives.
The problem is starkly illustrated by the case of insulin. Discovered in the early 20th century, one might expect this life-saving medication to be a widely available, inexpensive generic. However, the reality is far more complex. As medical researcher Jing Luo explained, modern insulins are vastly different from their predecessors, having undergone significant molecular modifications. These advancements, while medically beneficial, have been the subject of numerous patents. Each patent grants the holder, typically a pharmaceutical company, a period of market exclusivity, effectively creating a monopoly and preventing generic competition.
The Strategy of Patent Stacking
Pharmaceutical companies have become adept at employing a strategy known as "patent stacking," or creating "patent thickets." This involves filing dozens of patents on various aspects of a single drug. As Jing Luo elaborated, these patents can cover the active ingredient itself, its medical uses, the non-active excipients used in its formulation, and even the delivery devices. The sheer volume and complexity of these patents create a formidable barrier for potential generic competitors. A company seeking to introduce a generic version might face lawsuits for infringing on any one of these numerous patents, making the legal and financial risks prohibitively high.
A standard patent provides a 20-year monopoly. However, under laws like the Hatch-Waxman Act, drugs can receive an additional five years of market exclusivity. The practice of filing secondary patents, often years after the initial patent, can further extend this protection. This strategy significantly delays the market entry of generic versions, allowing brand-name manufacturers to maintain high prices for extended periods.
A prime example is the case of Wegovy and Ozempic. While the original patent on the active ingredient expired this year, the additional five-year extension pushes exclusivity into the early 2030s. However, the multitude of secondary patents filed by the manufacturers could potentially delay the availability of cheaper generic versions in the U.S. until 2042 or even later. This practice is not a hidden secret; it’s a well-understood industry strategy. Pharmaceutical CEOs often refer to their "robust patent portfolios" as a means to reassure investors and deter generic competition, effectively promising continued profitability through extended monopolies.
The Genesis of the Patent Thicket: Al Engelberg’s Story
Understanding how these patent strategies evolved requires a look back at the history of generic drugs in America and the pivotal role of individuals like Alfred Engelberg, an 86-year-old lawyer who has spent decades navigating and shaping this complex landscape. Engelberg’s early life experiences in Atlantic City, a city known for its hustle and inherent distrust, instilled in him a keen understanding of human nature and the art of negotiation. From collecting loose change under the boardwalk to working at an illegal mob-run bingo game, he learned to expect that everyone has an angle.
This upbringing proved invaluable when Engelberg began his career as a patent examiner while attending law school at night. He observed that the patent system was susceptible to exploitation, partly due to the often-underpaid and overworked examiners who were frequently using their time to study for law school exams. The core of a patent examiner’s job is to determine if an invention is novel and non-obvious to a person of ordinary skill in the relevant field. However, many examiners lacked the practical experience to make such nuanced judgments, granting monopolies for 17 years (the then-standard term) on inventions that might have been readily apparent to those in the industry.
Engelberg, with his background in chemical engineering and experience in manufacturing plants, specialized in areas he understood. This expertise led to promotions and eventually a recruitment by a corporate law firm. He later moved to the Department of Justice, gaining valuable litigation experience, before entering private practice in New York City in 1968, ready to "tear the world apart."
The Birth of the Generic Drug Industry and Hatch-Waxman
The generic drug market in the 1970s was nascent, dominated by a few family-owned businesses primarily selling drugs approved before 1962, when the Food and Drug Administration (FDA) began requiring rigorous clinical trials for safety and efficacy. These smaller companies lacked the capital for such trials, limiting them to older medications. Consequently, generic drugs accounted for only about 20% of prescriptions.
Engelberg’s entry into generic drug litigation began serendipitously in 1973 when a bank, representing a bankrupt client named Premo Pharmaceuticals, contacted him. The client was being sued for patent infringement, and the bank offered a meager $10,000 for a defense. Despite the dire circumstances and a seemingly weak legal position, Engelberg recognized the patent owner’s vulnerabilities: winning would yield nothing from a bankrupt company, while losing would open the floodgates to generic competition and millions in lost revenue. He skillfully bluffed his way through an initial court conference, impressing the judge with his confidence. This strategic maneuver led to a settlement, allowing Premo Pharmaceuticals to emerge from bankruptcy with $400,000.
This success quickly established Engelberg’s reputation in the burgeoning generic drug world. By the late 1970s, a growing awareness of high drug prices fueled efforts by generic drug companies to lobby for easier market entry. The brand-name manufacturers countered by emphasizing the lengthy development and approval processes for their patented drugs.
In 1983, a significant legislative effort began to forge a compromise. Spearheaded by Representative Henry Waxman and Senator Orrin Hatch, this endeavor culminated in the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act. Engelberg played a crucial role, commuting to Washington D.C. for over a year to strategize for the generic drugmakers. He viewed this as a monumental opportunity, far beyond a typical legal case, to influence legislation with profound consequences.
The Hatch-Waxman Act comprised three key components:
- Patent Term Restoration: Brand-name drugmakers received an extension on their patent terms to compensate for time lost during the FDA approval process.
- Abbreviated New Drug Application (ANDA): A streamlined pathway was created for generic drugmakers to gain FDA approval by demonstrating bioequivalence to the brand-name drug, rather than repeating costly clinical trials.
- Patent Challenge Provisions: The law outlined rules for generic drugmakers challenging existing patents.
Engelberg’s expertise, honed by his experiences, was instrumental in shaping these patent challenge provisions. While the Act aimed to foster generic competition, a particular outcome of these negotiations would have unintended and far-reaching consequences.
The Rise of "Pay for Delay"
The Hatch-Waxman Act created a powerful incentive for generic companies: a successful patent challenge granted them a six-month period of market exclusivity before other generic manufacturers could enter. This exclusivity, combined with the significantly lower cost of production for generic drugs compared to branded ones, could lead to immense profits.
Engelberg, reflecting on his role, realized a lucrative opportunity. He conceived of a strategy where he would partner with a generic drug manufacturer, identify drugs with weak patents, challenge those patents, and split the substantial profits generated during the exclusivity period. This "bounty hunting" operation, as he described it, was met with initial resistance from his law firm partners. Undeterred, Engelberg left to pursue this venture independently, working tirelessly for ten years without hiring staff, even to type.
His efforts paid off handsomely. In one of his earliest cases, he personally netted over $70 million. The practice of generic companies challenging patents and receiving financial settlements from brand-name manufacturers to delay market entry became known as "pay for delay." This arrangement proved immensely profitable for both parties involved: the brand-name company avoided losing its monopoly and paid a settlement that was significantly less than potential lost revenue, while the generic partner secured a substantial payout and a protected market entry.
The Buspar case in the mid-1990s exemplifies this phenomenon. Buspar, an anti-anxiety drug, was marketed aggressively by Bristol-Myers Squibb, generating over $200 million annually. The patent was based on a claim of a new use for a known tranquilizer, a concept Engelberg found questionable. He filed a motion arguing the patent was invalid based on its face value, akin to patenting the use of sugar as a sweetener. Bristol-Myers Squibb, facing significant financial exposure, offered $25 million to settle. Engelberg’s team countered, and ultimately a settlement of $72 million was reached.
The consequences for the public were substantial. Bristol-Myers Squibb maintained its monopoly on Buspar for an additional five years, grossing approximately $2 billion in profits. The drug, which could have been available for cents per pill, continued to be sold at inflated prices. Engelberg recognized that this "pay for delay" model, while lucrative for the companies involved, systematically disadvantaged consumers.
Engelberg’s Reassessment and Advocacy
The widespread adoption of "pay for delay" schemes, fueled by the economics of patent litigation, became a major concern for Engelberg. While the Hatch-Waxman Act had successfully increased generic drug utilization from 20% to around 90%, the "pay for delay" loophole and the proliferation of secondary patents—the "patent thickets"—undermined the law’s intent to provide affordable medications.
By the mid-1990s, Engelberg had amassed significant wealth. He retired from his active legal practice and began a new phase of his career: advocacy for reform. He published articles, arguing for a reboot of the Hatch-Waxman Act, suggesting even the six-month exclusivity period for successful challenges might be too generous. He has since invested millions in research, public awareness campaigns, and established an intellectual property law center at NYU, his alma mater.
His efforts highlight the escalating nature of the problem. In 1999, he noted about two dozen patent challenges had been filed. Today, he estimates that number has ballooned to twelve thousand, representing tens of billions of dollars in legal fees and a burgeoning industry for large law firms.
The Challenge of Biologics and Future Reforms
The landscape of pharmaceutical innovation has also shifted dramatically. Many of today’s top-selling drugs are "biologics," complex medications like insulin, Humira, and Enbrel, which are not covered by the original Hatch-Waxman Act. A separate law, the Biologics Price Competition and Innovation Act of 2010, was enacted to address these. However, Engelberg contends that this law exacerbates the problems of the Hatch-Waxman Act, "multiplied by 10 and deliberately," encouraging patent thickets and lacking a robust pathway for challenges. He draws parallels to the early days of the computer industry, where IBM’s extensive patent portfolios could stifle nascent companies.
Despite these challenges, Engelberg remains committed to reform. His 2025 book, "Breaking the Medicine Monopolies," outlines his proposals, which extend beyond merely patching loopholes. He advocates for increased government involvement in price negotiation and regulation, suggesting that the government could leverage its authority under a 1980 law to commission generic versions of drugs developed with public research funds. Furthermore, he believes the FDA’s interpretation of patent rules that facilitate patent thicketing is fundamentally flawed and is actively exploring legal challenges, even employing AI tools like Claude to assist in his efforts.
At 86, Engelberg’s dedication stems from a deep sense of obligation. Having profited immensely from the system he helped shape, he feels compelled to address its shortcomings. His work is a testament to the idea that understanding the intricate mechanisms of drug pricing, from the history of patent law to the strategies employed by pharmaceutical giants, is crucial for consumers seeking access to affordable healthcare.
The upcoming U.S. Supreme Court case that could further restrict the generic drug pipeline underscores the urgency of these issues. As the legal and economic battles over prescription drug pricing continue, the insights and ongoing efforts of individuals like Al Engelberg are vital for navigating the complex path toward more equitable access to medication.
